What we do
Cardiac imaging
Mangafodipir is the only MRI contrast agent with a potential to quantify alterations in calcium handling and contractility in heart diseases.
With mangafodipir-enhanced MRI, physicians may measure the rate of influx of manganese into cardiomyocytes as a direct measure of calcium channel activity. Altered channel activity occurs in ischemic heart disease, in dilated and hypertrophic cardiomyopathies and in heart failure. Our procedure will be a game changer for MR imaging of the heart.
IC Targets successfully validated this novel MRI procedure in a non-clinical study. Mangafodipir-enhanced MRI was able to detect altered calcium channel activity and loss of T-tubule in an animal model.
Currently we are enrolling participants in a Phase 2A Proof-of-Concept clinical trial in Norway. This trial is evaluating the efficacy and safety of mangafodipir-enhanced MRI for assessment of myocardial calcium channel activity in patients suffering from heart failure with preserved ejection fraction (HFpEF), caused by hypertrophic cardiomyopathy or cardiac amyloidosis.
We are planning to conduct a clinical program in heart failure patients, particularly in patients suffering from HFpEF, which represent about 50% of heart failure cases and where the need for improved diagnosis and treatment is most urgent.
More than 50 million patients in the seven major markets have heart disease. Heart disease is a leading cause of death in the USA and Europe. Our long-term goal is to obtain global approval for mangafodipir-enhanced MRI in all common heart diseases where calcium handling may be altered. Assessment of calcium channel activity with mangafodipir- enhanced MRI will provide a tool for improved diagnosis, improved selection of therapy and monitoring of treatment efficacy in these patients.
IC Targets’ procedure is covered by granted patents and additional filed patent applications for the new uses of mangafodipir.